Passage Bio Inc (PASG)
1.59
+0.18
(+12.77%)
USD |
NASDAQ |
May 07, 10:04
Passage Bio Cash from Investing (TTM): 65.24M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 65.24M |
September 30, 2023 | 54.28M |
June 30, 2023 | 27.07M |
March 31, 2023 | 29.10M |
December 31, 2022 | 25.20M |
September 30, 2022 | 24.95M |
June 30, 2022 | 18.16M |
March 31, 2022 | -8.106M |
December 31, 2021 | -45.81M |
Date | Value |
---|---|
September 30, 2021 | -78.76M |
June 30, 2021 | -202.57M |
March 31, 2021 | -192.40M |
December 31, 2020 | -172.11M |
September 30, 2020 | -135.60M |
June 30, 2020 | -0.345M |
March 31, 2020 | -0.908M |
December 31, 2019 | -1.693M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-202.57M
Minimum
Jun 2021
65.24M
Maximum
Dec 2023
-34.96M
Average
-0.908M
Median
Mar 2020
Cash from Investing (TTM) Benchmarks
NovaBay Pharmaceuticals Inc | -0.019M |
Palatin Technologies Inc | 9.293M |
iBio Inc | 8.285M |
Theriva Biologics Inc | -0.202M |
Oragenics Inc | -0.9363M |